We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Dyne Therapeutics Inc
5 own
5 watching
Current Price
$12.66
$0.19
(1.52%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
704.36M
52-Week High
15.63
52-Week Low
4.3
Average Volume
0.21M
Dividend Yield
--
P/E Ratio
-1.35986159
Market Capitalization704.36M52-Week High15.6352-Week Low4.3Average Volume0.21MDividend Yield--P/E Ratio-1.35986159What does the Dyne Therapeutics Inc do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Read More
How much money does Dyne Therapeutics Inc make?
News & Events about Dyne Therapeutics Inc.
Globe Newswire
2 months ago
- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCEPlatform Achieves Robust Exon Skipping, Restores Dystrophin at the Sarcolemma and Halts Progression of Fibrosis in a Severe In Vivo Model of Duchenne...
Globe Newswire
2 months ago
- Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD - WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing ...
Ticker Report
4 months ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Ticker Report
4 months ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Globe Newswire
4 months ago
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Dyne Therapeutics Inc share price today?
Can Indians buy Dyne Therapeutics Inc shares?
How can I buy Dyne Therapeutics Inc shares from India?
Can Fractional shares of Dyne Therapeutics Inc be purchased?
What are the documents required to start investing in Dyne Therapeutics Inc stocks?
What is today’s traded volume of Dyne Therapeutics Inc?
What is today’s market capitalisation of Dyne Therapeutics Inc?
What is the 52-Week High and Low Range of Dyne Therapeutics Inc?
What percentage is Dyne Therapeutics Inc down from its 52-Week High?
What percentage is Dyne Therapeutics Inc up from its 52-Week Low?
Current Price
$12.66
$0.19
(1.52%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.